Prophylactic HPV vaccination and anal cancer

Stier, Elizabeth A.; Chigurupati, Nagasudha L.; Fung, Leslie

doi:10.1080/21645515.2016.1149274

Cited by 45 publications

(37 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Prophylactic HPV vaccination is part of the individual immunisation schedule in many countries, although the country-specific performance varies considerably (21). Besides the effect on the uterine cervix, the quadrivalente HPV vaccine was demonstrated to prevent persistent anal HPV infection and anal intraepithelial lesions (22). The five most prevalent anal HPV genotypes found in the present study were HPV types 16, 18, 31, 52 and 51.…”

Section: Discussionmentioning

confidence: 62%

Prevalence of human papillomavirus infection of the anal canal in women: A prospective analysis of high-risk populations

et al. 2017

View full text Add to dashboard Cite

Abstract. Infection with certain types of human papillomavirus (HPV) has been associated with the development of cervical and anal cancer. Worldwide, the incidence of anal cancer has increased markedly. The present study aimed to evaluate the prevalence of HPV infection of the uterine cervix and anal canal in human immunodeficiency virus (HIV)-and non-HIV-infected risk populations. Cervical and anal HPV swabs and cytology samples were collected from 287 patients at the University Hospital of Munich, Germany between 2011 and 2013. Patients were divided into HIV-negative controls (G1) and two risk groups, including HIV-negative patients with cytological abnormalities of the cervix (G2) and HIV-infected patients (G3). Data, including clinical parameters, were analysed. The risk groups had significantly more positive results for HPV in the anus (71.03 and 83.15% for G2 and G3, respectively), as compared with G1. The predominant HPV genotypes found in the anus were high-risk HPV genotypes, which were significantly correlated with concomittant cervical HPV findings. In the risk groups, a significant association between the cytological findings and HPV detection in the cervix was found, while the results of the anus revealed no significance. The results of the present study suggested that the prevalence of HPV infection in the anal canal of risk populations is high. Furthermore, patients with abnormal cervical cytology results and HIV-infected women, irrespective of their individual cervical findings, may have a risk of concomittant anal high-risk HPV infection. Based on the predominant HPV genotypes found in the study, HPV vaccination could reduce the incidence of anal cancer. Nevertheless, high-risk patients should be intensively screened for anal squamous intraepithelial abnormalities to avoid invasive cancer stages.

show abstract

Section: Discussionmentioning

confidence: 62%

Prevalence of human papillomavirus infection of the anal canal in women: A prospective analysis of high-risk populations

et al. 2017

View full text Add to dashboard Cite

show abstract

“…HPV vaccines have the potential to prevent HPV-related anal diseases (25). Although this evidence remains less robust, concerning the HPV-related oral diseases, the eventual preventive effect of HPV vaccines has been suggested (26,27).…”

Section: Discussionmentioning

confidence: 99%

High Prevalence of Human Papillomavirus on Anal and Oral Samples from Men and Women with External Anogenital Warts: The HERCOLES Study

Lisboa¹,

Santo²,

Azevedo³

et al. 2019

Acta Derm Venerol

View full text Add to dashboard Cite

SIGNIFICANCEHuman papillomavirus infection is highly prevalent in sexually active population and has been associated with anal and oropharyngeal cancers. This study estimates the prevalence of human papillomavirus on anal and oral samples from men and women with external anogenital warts. We found a high prevalence of human papillomavirus on extragenital sites (anal canal and oral mucosa) among patients with external anogenital warts. Both anal and oral human papillomavirus infections were more common in men who have sex with men than in heterosexual men. Anal highrisk HPV types (high risk as carcinogenic) were more common in women and in men who have sex with men. Overall, we demonstrated a high human papillomavirus burden in this population beyond anogenital warts, suggesting a greater impact of human papillomavirus vaccination.Human papillomavirus (HPV) infection is highly prevalent in the sexually active population. This study estimates the prevalence of HPV DNA in anal and oral samples from a cohort of men and women with incident anogenital warts. Anal and/or oral samples from 541 patients with anogenital warts were tested for 35 HPV genotypes using a PCR assay. The overall prevalence of anal HPV and oral HPV DNA was 59.9% (n = 305/509; 95% confidence interval (CI) 55.6-64.1%) and 14.5% (n = 78/538; 95% CI 11.8-17.7%), respectively. Among patients with perianal warts, the anal HPV DNA prevalence was 92.3% (95% CI 87.0-95.5%). Anal HPV DNA prevalence in patients with genital warts but no perianal warts was 55.7% (95% CI 50.6-60.7%). Both anal and oral HPV infections were more common in men who have sex with men than in heterosexual men (90.4% versus 38.5% and 20.8% versus 11.8%, respectively). Anal high risk-HPV infection was more common in women (58.8%) and in men who have sex with men (67.7%). We found that anogenital warts represent a clinical marker for both anal and oral HPV infections, including anal high risk-HPV infections, particularly among women and men who have sex with men. ActaDVActaDV Advances in dermatology and venereology Acta Dermato-Venereologica C. Lisboa et al. 558 www.medicaljournals.se/acta ActaDV ActaDV Advances in dermatology and venereology Acta Dermato-Venereologica 559 High HPV prevalence on anal and oral samples from patients with anogenital warts Acta Derm Venereol 2019 ActaDV ActaDV Advances in dermatology and venereology Acta Dermato-Venereologica C. Lisboa et al. 560 www.medicaljournals.se/acta ActaDV ActaDV Advances in dermatology and venereology Acta Dermato-Venereologica 561 High HPV prevalence on anal and oral samples from patients with anogenital warts Acta Derm Venereol 2019 ActaDV ActaDV Advances in dermatology and venereology Acta Dermato-Venereologica C. Lisboa et al. 562 www.medicaljournals.se/acta

show abstract

“…Indeed, since the MSM population should be considered at increased risk for non‐transient HPV infections, the administration of HPV vaccine to men prior to the onset of sexual activity could effectively prevent almost all anal cancers (primary prevention of squamous cell cancer of the anus, SCCA). In addition, the nonavalent HPV vaccine may be helpful in preventing recurrent high‐grade squamous anal intraepithelial lesions (anal intraepithelial neoplasia [AIN] 2 or greater) and possibly the progression to SCCA, especially in individuals at increased risk including all HIV infected subjects (men and women) and HIV uninfected MSM . Nevertheless, the potential impact of nonavalent HPV vaccine in reducing the global burden of HPV‐related cancers could be affected by vaccine uptake and coverage, availability, and affordability.…”

Section: Discussionmentioning

confidence: 99%

Prevalence of anal, oral, penile and urethral Human Papillomavirus in HIV infected and HIV uninfected men who have sex with men

Ucciferri

Tamburro

Falasca

et al. 2017

Journal of Medical Virology

View full text Add to dashboard Cite

Aims of the study were to evaluate Human Papillomavirus (HPV) and type-specific prevalence in four anatomical sites in HIV infected men who have sex with men (MSM) compared with HIV uninfected MSM. Participants were recruited among the attendees of Infectious Diseases Clinics in Central Italy. A trained medical practitioner collected by interview sociodemographic data and information on medical history, sexual behavior, and drug use. Swabs from anal canal, oral cavity, urethral mucosa, and coronal sulcus were tested for HPV DNA and genotyping. Ninety MSM were enrolled, 45 subjects within each group. Overall, 48.9% MSM were HPV positive and prevalence was higher in HIV infected men (60.0% vs 37.8%, P = 0.035). HPV at multiple anatomic sites occurred in 59.1% MSM, with 34.1% and 22.7% at two and three sites, respectively. Prevalence of anal, coronal sulcus, oral, and urethral HPV was 96.3%, 37%, 21.6%, and 18.5% in HIV infected MSM, and 70.6%, 70.6%, 29.4%, and 23.5% among HIV uninfected. A similar proportion of HIV infected and uninfected MSM (59.2% and 58.8%) carried at least one high-risk genotype. Prevalence of types covered by nonavalent vaccine was 77.8% in HIV infected compared with 82.3% in HIV uninfected MSM. HPV 58 and 16 were mostly detected in HIV positive (43.7% and 31.2%) and negative MSM (50.0% and 40.0%). HPV detection rate underlined the high vulnerability of MSM to acquire multisite infections, characterized by various genotype combinations. Since nonavalent vaccine could have prevented 80% of HPV infections, study findings support the implementation of vaccination programs among MSM.

show abstract

Prophylactic HPV vaccination and anal cancer

Cited by 45 publications

References 17 publications

Prevalence of human papillomavirus infection of the anal canal in women: A prospective analysis of high-risk populations

Prevalence of human papillomavirus infection of the anal canal in women: A prospective analysis of high-risk populations

High Prevalence of Human Papillomavirus on Anal and Oral Samples from Men and Women with External Anogenital Warts: The HERCOLES Study

Prevalence of anal, oral, penile and urethral Human Papillomavirus in HIV infected and HIV uninfected men who have sex with men

Contact Info

Product

Resources

About